Sildenafil in the treatment of pulmonary hypertension
The paper describes the clinical use of a phosphodiesterase 5 inhibitor (sildenafll) in a patient with primary pulmonary hypertension during a long-term controlled follow-up. The 6-year use of sildenafll as monotherapy for pulmonary hypertension had a significant positive effect as a decrease in the...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ltd. “The National Academy of Pediatric Science and Innovation”
2016-03-01
|
| Series: | Rossijskij Vestnik Perinatologii i Pediatrii |
| Subjects: | |
| Online Access: | https://www.ped-perinatology.ru/jour/article/view/286 |
| Summary: | The paper describes the clinical use of a phosphodiesterase 5 inhibitor (sildenafll) in a patient with primary pulmonary hypertension during a long-term controlled follow-up. The 6-year use of sildenafll as monotherapy for pulmonary hypertension had a significant positive effect as a decrease in the functional class of pulmonary hypertension from 3 to 1, an increase in exercise tolerance, improvements in echocardiographic parameters and biochemical markers (brain natriuretic peptide), and a rise in oxygen uptake during cardiorespiratory testing. |
|---|---|
| ISSN: | 1027-4065 2500-2228 |